nVent Electric vs Zimmer Biomet Holdings Inc — how do they compare? nVent Electric trades at $158.7 (market cap $26.31B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: nVent Electric is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.02%). Which is the better fit depends on your goals.
| NVT | ZBH | |
|---|---|---|
Market Cap | $26.31B | $17.97B |
Sector | Industrials | Health |
52-Week High | $184.34 | $104.26 |
52-Week Low | $94.78 | $79.58 |
Enterprise Value | $27.69B | $25.04B |
Dividend Yield | 0.52% | 1.02% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Trailing returns across standard periods
Latest headlines on both assets
nVent provides electrical connection and protection solutions, including enclosures, fastening systems, and thermal management products. Its products help support electrical and industrial infrastructure across multiple end markets.
Read more on NVT →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →